What are the key international policy positions addressing pharmacogenomics?
An article in the editorial GenEdit entitled Consent in Pharmacogenomic Research reveals that there are few policies in this domain and specifies the importance of establishing a clear international framework in order to guide researchers in pharmacogenomics. • In 2007, the final version of the ICH Harmonized Tripartite Guideline, E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding was approved. This directive defines, among other things, the terminology of pharmacogenomics (for example, concepts around samples and information, such as identified, coded, double coded, anonymized, etc). • The statement of the Human Genome Organisation’s (HUGO) ethics committee, entitled HUGO Statement of Pharmacogenomics (PGx): Solidarity, Equity and Governance contains recommendations related to the governance of pharmacogenomic research.
An article in the editorial GenEdit entitled Consent in Pharmacogenomic Research (2007) reveals that there are few policies in this domain and specifies the importance of establishing a clear international framework in order to guide researchers in pharmacogenomics. • In 2007, the final version of the ICH Harmonized Tripartite Guideline, E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding was approved. This directive defines, among other things, the terminology of pharmacogenomics (for example, concepts around samples and information, such as identified, coded, double coded, anonymized, etc). • The statement of the Human Genome Organisation’s (HUGO) ethics committee, entitled HUGO Statement of Pharmacogenomics (PGx): Solidarity, Equity and Governance contains recommendations related to the governance of pharmacogenomic research. This directive emphasizes the importance that research be guided by a concern for equity rather than so